Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Avalo Therapeutics (AVTX) Leases (2019 - 2025)

Avalo Therapeutics' Leases history spans 7 years, with the latest figure at $336000.0 for Q4 2025.

  • For Q4 2025, Leases fell 54.66% year-over-year to $336000.0; the TTM value through Dec 2025 reached $336000.0, down 54.66%, while the annual FY2025 figure was $336000.0, 54.66% down from the prior year.
  • Leases reached $336000.0 in Q4 2025 per AVTX's latest filing, down from $402000.0 in the prior quarter.
  • In the past five years, Leases ranged from a high of $2.0 million in Q4 2021 to a low of $336000.0 in Q4 2025.
  • Average Leases over 5 years is $1.2 million, with a median of $1.2 million recorded in 2024.
  • Peak YoY movement for Leases: skyrocketed 159.74% in 2022, then plummeted 64.71% in 2025.
  • A 5-year view of Leases shows it stood at $2.0 million in 2021, then fell by 12.54% to $1.8 million in 2022, then decreased by 24.06% to $1.3 million in 2023, then plummeted by 44.24% to $741000.0 in 2024, then crashed by 54.66% to $336000.0 in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Leases are $336000.0 (Q4 2025), $402000.0 (Q3 2025), and $487000.0 (Q2 2025).